# RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

> **NCT00809185** · PHASE2 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** everolimus
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** Bone marrow aspirate/biopsy

## Key facts

- **NCT ID:** NCT00809185
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2019-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00809185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00809185, "RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00809185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*